# Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

> **NCT04109482** · PHASE1,PHASE2 · TERMINATED · sponsor: **Mustang Bio** · enrollment: 3 (actual)

## Conditions studied

- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

## Interventions

- **BIOLOGICAL:** MB-102
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT04109482
- **Lead sponsor:** Mustang Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-17
- **Primary completion:** 2023-05-17
- **Final completion:** 2023-05-17
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Business reasons.
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04109482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04109482, "Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04109482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*